CBio Shareholders Approve Merger With Inversion Inc

  • 79% of shares were voted in favour
  • Merged company to be called Invion Limited
  • Two clinical-stage drug candidates targeting three initial indications
  • Phase II asthma and phase II chronic bronchitis studies to be initiated in 2012
Posted in ASX Releases